Fig 1.
Activation of S100A12 and IFI27 in a significant portion of hospitalized COVID-19 patients compared to healthy controls (whole blood).
A) upper panel (dataset GSE152641), comparison of S100A12 and IFI27 expression in healthy controls and hospitalized COVID-19 patients. B) lower panel (dataset GSE171110), comparison of S100A12 and IFI27 expression in healthy controls and severe COVID-19 patients.
Fig 2.
Expression level of S100A12 and IFI27 in hospitalized patients with and without COVID-19 (whole blood).
A) upper panel (dataset GSE167000), comparison of S100A12 and IFI27 expression in non-critical patients with and without COVID-19. B) lower panel (dataset GSE154998), comparison of S100A12 and IFI27 expression in intensive care unit (ICU) patients with and without COVID-19.
Fig 3.
Expression level of S100A12 and IFI27 in COVID-19 patients with different severity (whole blood).
A) upper panel (dataset GSE172114), comparison of S100A12 and IFI27 expression in moderate and critical COVID-19 patients. B) lower panel (dataset Zenodo 6120249), comparison of S100A12 and IFI27 expression in COVID-19 patients with different severity (non-hospitalized, moderate, severe and critical).
Fig 4.
Correlation of S100A12 expression and the severity of COVID-19 (whole blood).
A) upper panel (dataset GSE189990), comparison of S100A12 expression in COVID-19 patients with different severity (incidental, moderate, critical and fatal). B) lower panel (dataset GSE161777), correlation between S100A12 expression and severity index (from critical to recovery).
Fig 5.
Expression level of S100A12 and IFI27 in COVID-19 patients and patients with other diseases (whole blood).
A) upper panel (dataset GSE161731), comparison of S100A12 and IFI27 expression in healthy controls and patients with COVID-19 (hospitalized and non-hospitalized) or other types of infection. B) lower panel (dataset GSE157103), comparison of S100A12 and IFI27 expression in intensive care unit (ICU) and non-ICU patients with or without COVID-19.
Fig 6.
Correlation of IFI27 expression with the duration of COVID-19 infection.
A) upper left (dataset Zenodo 6120249), correlation between IFI27 expression and time since symptom onset in COVID-19 patients. B) upper right (dataset GSE155454), correlation between IFI27 expression and time since symptom onset in COVID-19 patients. C) lower panel (dataset GSE166190), correlation between IFI27 expression and time interval index in COVID-19 patients (both adults and children).
Fig 7.
Longitudinal tracking of the expression level of IFI27 and S100A12 during the course of infection.
A) upper left (dataset GSE68310), tracking of IFI27 expression in a community cohort with seasonal influenza. B) upper right (dataset GSE161731), tracking of IFI27 expression in non-hospitalized patients with COVID-19. C) lower left (dataset GSE178967), change of IFI27 expression in COVID-19 patients 5 days after study enrollment. D) lower right (dataset GSE169687), long-term tracking of S100A12 expression in COVID-19 patients.
Fig 8.
Expression level of S100A12 and IFI27 in peripheral blood mononuclear cells (PBMCs) as correlated with COVID-19 severity or disease duration (dataset GSE152418).
A) upper panel, comparison of S100A12 and IFI27 expression in healthy controls and COVID-19 patients with different severity (moderate, severe and critical). B) lower panel, correlation between IFI27 expression and time since symptom onset in COVID-19 patients.
Fig 9.
Expression levels of S100A12 and IFI27 in peripheral blood mononuclear cells (PBMCs) as markers for the infection in COVID-19 patients.
A) upper panel (dataset GSE184401), comparison of S100A12 and IFI27 expression in COVID-19 patients with different severity (mild or severe) and secondary infection (with or without). B) lower panel (dataset GSE179627), comparison of S100A12 and IFI27 expression in healthy controls and COVID-19 patients with different severity (asymptomatic, mild and moderate) and different stages (acute, recovering and re-positive).